私人保险儿童的疫苗接种覆盖率:美国调查数据与行政数据的比较
本研究于2021年开展回顾性分析,利用2015—2018年MarketScan商业理赔与就诊数据库及2018—2019年医疗保健效果数据与信息集(HEDIS),评估私人保险儿童2岁前接种咨询委员会(ACIP)推荐疫苗的覆盖率,并与2016—2018年全国儿童免疫调查(NIS-Child)估计值进行统计比较。结果显示不同数据源估计值差异范围为0.1至7.2个百分点,部分疫苗/剂次的差异具有统计学显著性;结论认为对某些疫苗和关注人群,三类数据可能给出可比的私人保险儿童覆盖率。
要点
- MarketScan估计覆盖率从69.9%(≥2剂流感疫苗)到95.0%(≥3剂百白破疫苗)。
- HEDIS估计覆盖率从68.0%(≥2剂流感疫苗)到92.2%(≥1剂麻腮风疫苗)。
- 作者认为对某些疫苗和关注人群,NIS-Child、MarketScan与HEDIS数据可能给出可比的私人保险儿童覆盖率。
核心结论
- 对某些疫苗和关注人群,NIS-Child、MarketScan商业理赔与就诊数据及HEDIS数据可能给出可比的私人保险儿童覆盖率。
研究设计与样本
- 2021年开展的回顾性分析,使用2015—2018年MarketScan商业理赔与就诊数据库及2018—2019年HEDIS数据,评估私人保险儿童2岁前ACIP推荐疫苗的接种覆盖率,并与2016—2018年NIS-Child估计值进行统计比较。
主要发现
- MarketScan估计覆盖率范围为69.9%(≥2剂流感疫苗)至95.0%(≥3剂白喉、破伤风类毒素和无细胞百日咳疫苗)。
- HEDIS估计覆盖率范围为68.0%(≥2剂流感疫苗)至92.2%(≥1剂麻疹、腮腺炎和风疹疫苗)。
- MarketScan与NIS-Child估计值差异范围为0.1至4.3个百分点,在13种评估疫苗/剂次及未接种任何疫苗儿童比例中有6项差异具有统计学显著性。
- HEDIS与NIS-Child估计值差异范围为0.4至7.2个百分点,在10种评估疫苗/剂次中有6项差异具有统计学显著性。
临床怎么用
- 作者认为,对于某些疫苗和关注人群,NIS-Child、MarketScan商业理赔与就诊数据及HEDIS数据可能给出可比的私人保险儿童覆盖率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: National Immunization Survey-Child data are used widely to assess childhood vaccination coverage in the U.S. This study compares National Immunization Survey-Child coverage estimates with estimates using other supplementary data sources. METHODS: Retrospective analyses in 2021 assessed vaccination coverage of privately insured children for vaccines recommended by the Advisory Committee on Immunization Practices by age 2 years, using the 2015-2018 MarketScan Commercial Claims and Encounters databases and the 2018-2019 Healthcare Effectiveness Data and Information Set. The coverage estimates were compared statistically with those using the 2016-2018 National Immunization Survey-Child. RESULTS: Estimated coverage ranged from 69.9% (≥2 doses of influenza vaccine) to 95.0% (≥3 doses of diphtheria, tetanus toxoids, and acellular pertussis vaccine) using the MarketScan Commercial Claims and Encounters data and from 68.0% (≥2 doses of influenza vaccine) to 92.2% (≥1 dose of measles, mumps, and rubella vaccine) using the Healthcare Effectiveness Data and Information Set. The difference between the MarketScan Commercial Claims and Encounters and National Immunization Survey-Child estimates ranged from 0.1 to 4.3 percentage points and was statistically significant for 6 of the 13 assessed vaccines/doses and percentage of children receiving no vaccinations. The difference between the Healthcare Effectiveness Data and Information Set and National Immunization Survey-Child estimates ranged from 0.4 to 7.2 percentage points and was statistically significant for 6 of the 10 assessed vaccines/doses. CONCLUSIONS: For certain vaccines and populations of interest, the National Immunization Survey-Child, MarketScan Commercial Claims and Encounters, and Healthcare Effectiveness Data and Information Set data might give comparable coverage of privately insured children.
引用
- Hong K, Hill HA, Tsai Y, et al. Vaccination Coverage of Privately Insured Children: Comparing U.S. Survey and Administrative Data. Am J Prev Med. 2022. PMID: 35317958. doi:10.1016/j.amepre.2022.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。